- Pharmaceutical biotechnology company Innocan Pharma (CSE:INNO) announced a significant milestone in its global intellectual property strategy
- The Mexican Institute of Industrial Property (IMPI) has issued a Notice of Allowance for Innocan’s patent application covering its proprietary topical pain-relief formulation
- The company explained that this newly approved patent protects a unique blend of cannabidiol (CBD) and minerals designed to deliver fast-acting, localized pain relief
- Innocan Pharma stock (CSE:INNO) last traded at $0.16
Pharmaceutical biotechnology company Innocan Pharma (CSE:INNO) announced a significant milestone in its global intellectual property strategy.
The Mexican Institute of Industrial Property (IMPI) has issued a Notice of Allowance for Innocan’s patent application covering its proprietary topical pain-relief formulation.
In a media statement, the company explained that this newly approved patent protects a unique blend of cannabidiol (CBD) and minerals designed to deliver fast-acting, localized pain relief. Clinical studies have shown that the formulation provides noticeable pain reduction within just 20 minutes of application, underscoring its potential as a next-generation therapeutic solution.
The Mexican patent joins previously granted counterparts in the United States and Ukraine, reinforcing Innocan’s expanding global IP portfolio. The company also maintains a growing number of pending applications in key jurisdictions worldwide.
With this latest development, Innocan Pharma is able to strengthen its presence in Latin America, a region with increasing demand for advanced, non-invasive pain relief solutions. The company continues to explore partnerships and commercialization opportunities to bring its products to market.
Innocan Pharma Corp. is active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the company aims to provide non-opioid chronic pain management solutions for both animals and people.
Innocan Pharma stock (CSE:INNO) last traded at $0.16.
Join the discussion: Find out what everybody’s saying about this stock on the Innocan Pharma Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
